Living imaging tests and a tumor growth dynamic study confirmed that the dose of PLGA-DARPin9_29 that was virtually non-effective for HER2+ tumor imaging and therapy in a one-step strategy led to effective diagnostics and treatment with a two-step strategy. Here, ERBB2 is linked to neoplasm.